Research on diagnosing and treating low blood sugar levels
Fasting Hypoglycemia: Diagnosis and Treatment
This study is testing how to better diagnose and treat low blood sugar in people with insulinomas while they receive care at a special clinic.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1500 (estimated) |
| Ages | 18 Years to 120 Years |
| Sex | All |
| Sponsor | National Institutes of Health Clinical Center (CC) NIH |
| Locations | 1 site (Bethesda, Maryland) |
| Trial ID | NCT00001276 on ClinicalTrials.gov |
What this trial studies
This study focuses on understanding the causes and treatment of hypoglycemia, particularly in patients with insulinomas. Participants will undergo fasting blood tests to evaluate their blood sugar and insulin levels, while being monitored and treated as necessary. The study aims to identify new biomarkers for insulinomas and create a clinical data repository for future research. Patients will be admitted to the Clinical Center of the National Institutes of Health for thorough evaluation and care.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older with documented fasting blood glucose levels below 55 mg/dl and biochemical evidence of insulinoma or other pancreatic neuroendocrine tumors.
Not a fit: Patients with significant cardiac disease, those who are pregnant, or those deemed medically unstable will not benefit from this study.
Why it matters
Potential benefit: If successful, this research could lead to improved diagnosis and treatment options for patients suffering from low blood sugar levels.
How similar studies have performed: While this study builds on existing knowledge of hypoglycemia and insulinomas, it aims to explore new avenues and biomarkers, indicating a novel approach in this area.
Eligibility criteria
Show full inclusion / exclusion criteria
* INCLUSION CRITERIA: In order to be eligible to participate in this study, an individual must meet all of the following criteria: 1. Male, females ages \>= 18. 2. Patients with documented fasting blood glucose below 55 mg/dl. 4\. Patients with biochemical evidence for insulinoma or other pancreatic neuroendocrine tumors. EXCLUSION CRITERIA: An individual who meets any of the following criteria will be excluded from participation in this study: 1. Patients with significant cardiac disease will be excluded. 2. Subjects who are pregnant per self-report. 3. Medically unstable per the assessment of the PI.
Where this trial is running
Bethesda, Maryland
- National Institutes of Health Clinical Center — Bethesda, Maryland, United States (Recruiting)
Study contacts
- Principal investigator: Ranganath Muniyappa, M.D. — National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Study coordinator: Craig S Cochran, R.N.
- Email: craigc@bdg10.niddk.nih.gov
- Phone: (301) 402-1880
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.